Daily Bulletin

Business News

  • Written by Heidi Cuthbert


7 May 2018: Race Oncology Limited (“RAC”) released today a video interview with the Company’s new non-executive director, Dr John Cullity.

Dr Cullity trained as a haematology oncologist and became a specialist in the area of leukaemia. He has also held senior roles with Sanofi-Aventis and Schering-Plough in the US.

Based in New York, Dr Cullity now focuses on M&A and licensing transactions in the biopharma industry.

Commenting on Race Oncology’s first drug, Bisantrene, Dr Cullity said: “There is substantial opportunity for Bisantrene which is led by its activity in acute myeloid leukaemia.”

“Bisantrene has been shown to be active through immune-oncology pathways, which are so relevant to blockbuster agents that are currently being marketed by major pharmaceutical companies,” noted Dr Cullity.

“Additionally, it has unparalleled safety, particularly cardiac safety, which is so relevant and much sought-after by doctors within the anthracycline class.

He concluded: “Altogether, it’s a compelling package.”

In terms of the specific value he brings to the Race board, Dr Cullity noted: “I can help in several ways – firstly, through the evaluation of transactions as they come to light for Bisantrene with mid-to-large pharmaceutical companies.”

“Secondly, as the company considers additional assets that it might bring to build further investor value, I can assist with related assessment and negotiation.”

About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company’s first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of big pharma mergers.

 



g
INTERWEBS DIGITAL AGENCY

Pluralsight Encourages Technology Learners to Stay Home, Stay Safe, and Skill Up

Pluralsight, Inc. (NASDAQ: PS), the enterprise technology skills platform, today announced that in an effort to encourage technology learners around the world to stay safe and stay home, the compan...

Hotwire Global - avatar Hotwire Global

When do you need a follow-up email?

At some point in our lives, chances are we have followed-up on something or the other. This same idea extends to the space of email marketing, whether it is for a sales email or a job opportunity. Gi...

News Company - avatar News Company

5 Reasons Businesses Need An Excellent Content Marketer

First off what is a content marketer? Well, a content marketer is somebody responsible for the constant creation of visual, video, and written content for your brand. They should be somebody that ha...

Jake Patterson - avatar Jake Patterson

Australians Access Free Workforce and Collaboration Tools

Supporting Australian businesses with free access to crucial business services during the COVID-19 pandemic, the Australian Business Continuity site has seen over 14,000 visitors accessing the r...

Thrive PR - avatar Thrive PR

Taxes for Sports Betting in Australia

The gambling tax regulation varies from one country to the other. Australia ranks highest in terms of gambling. Over 80% of Australians are engaging in gambling of some type or the other. It is incl...

News Company - avatar News Company

Choosing a Media Agency in Sydney

Famously known as the Emerald City, Sydney is a vibrant coastal metropolis offering great business opportunities. Sydney is home to an influential startup culture. Having 35% of the startups in Aust...

Sarah Williams - avatar Sarah Williams


The Conversation

Politics

Prime Minister - Interview with Alan Jones, 2GB

JONES: Prime Minister good morning, thank you for your time.   PRIME MINISTER: Morning Alan.   JONES: Heavens above, have you had a sleep?    PRIME MINISTER: I got one last night. But now I’...

Alan Jones - avatar Alan Jones

NATIONAL COVID-19 COORDINATION COMMISSION

Today I announce the creation of a new National COVID-19 Coordination Commission (NCCC) that will coordinate advice to the Australian Government on actions to anticipate and mitigate the economic ...

Scott Morrison - avatar Scott Morrison

Prime Minister's interview with Alan Jones

ALAN JONES: Prime Minister, good morning.    PRIME MINISTER: Good morning, Alan.   JONES: Prime Minister, there are lots of ups and downs in your job, but you couldn't be anything but disappointed...

Scott Morrison and Alan Jones - avatar Scott Morrison and Alan Jones

ShowPo



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion